Which has stronger valuation & earnings, NMRA or RLMD?

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neumora Therapeutics N/A N/A -$236.93M -$1.23 N/A Relmada Therapeutics N/A N/A -$57.38M -$0.90 N/A

Is NMRA or RLMD more profitable?

Relmada Therapeutics' return on equity of -47.52% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neumora Therapeutics N/A -242.28% -131.32% Relmada Therapeutics N/A -47.52% -43.97%

Does the media prefer BIOA or NMRA?

In the previous week, BioAge Labs had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 4 mentions for BioAge Labs and 3 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.37 beat BioAge Labs' score of 0.72 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Neumora Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EYPT or NMRA?

In the previous week, Neumora Therapeutics had 1 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 3 mentions for Neumora Therapeutics and 2 mentions for Eyepoint Pharmaceuticals. Neumora Therapeutics' average media sentiment score of 1.37 beat Eyepoint Pharmaceuticals' score of 0.46 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neumora Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VNDA or NMRA?

In the previous week, Vanda Pharmaceuticals had 2 more articles in the media than Neumora Therapeutics. MarketBeat recorded 5 mentions for Vanda Pharmaceuticals and 3 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.37 beat Vanda Pharmaceuticals' score of 0.48 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neumora Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Neumora Therapeutics (NMRA) Competitors

$0.37 -0.07 (-15.34%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$0.41 +0.04 (+9.67%)

As of 08:28 AM Eastern

Compare

NMRA vs. RLMD, FENC, BIOA, EYPT, and VNDA

Should you buy Neumora Therapeutics stock or one of its competitors? Neumora Therapeutics's main competitors and comparable companies include Relmada Therapeutics (RLMD), Adherex Technologies (FENC), BioAge Labs (BIOA), Eyepoint Pharmaceuticals (EYPT), and Vanda Pharmaceuticals (VNDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Neumora Therapeutics compare to Relmada Therapeutics?

Neumora Therapeutics (NASDAQ:NMRA) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 26.9% of Neumora Therapeutics shares are held by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Neumora Therapeutics had 2 more articles in the media than Relmada Therapeutics. MarketBeat recorded 3 mentions for Neumora Therapeutics and 1 mentions for Relmada Therapeutics. Neumora Therapeutics' average media sentiment score of 1.37 beat Relmada Therapeutics' score of 0.95 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Neumora Therapeutics	Positive
Relmada Therapeutics	Positive

Relmada Therapeutics' return on equity of -47.52% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-242.28%	-131.32%
Relmada Therapeutics	N/A	-47.52%	-43.97%

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A

Neumora Therapeutics has a beta of 2.95, indicating that its stock price is 195% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

Neumora Therapeutics currently has a consensus target price of $6.57, suggesting a potential upside of 1,675.10%. Relmada Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 257.14%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Neumora Therapeutics is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Neumora Therapeutics beats Relmada Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Neumora Therapeutics compare to Adherex Technologies?

Neumora Therapeutics (NASDAQ:NMRA) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by company insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Neumora Therapeutics had 2 more articles in the media than Adherex Technologies. MarketBeat recorded 3 mentions for Neumora Therapeutics and 1 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 1.82 beat Neumora Therapeutics' score of 1.37 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Neumora Therapeutics	Positive
Adherex Technologies	Very Positive

Neumora Therapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Adherex Technologies' return on equity of -5.71% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-242.28%	-131.32%
Adherex Technologies	-6.09%	-5.71%	-2.37%

Adherex Technologies has higher revenue and earnings than Neumora Therapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A
Adherex Technologies	$44.64M	8.01	-$9.74M	-$0.13	N/A

Neumora Therapeutics has a beta of 2.95, meaning that its stock price is 195% more volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market.

Neumora Therapeutics currently has a consensus target price of $6.57, indicating a potential upside of 1,675.10%. Adherex Technologies has a consensus target price of $17.00, indicating a potential upside of 66.99%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Neumora Therapeutics is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Neumora Therapeutics beats Adherex Technologies on 8 of the 15 factors compared between the two stocks.

How does Neumora Therapeutics compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

In the previous week, BioAge Labs had 1 more articles in the media than Neumora Therapeutics. MarketBeat recorded 4 mentions for BioAge Labs and 3 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.37 beat BioAge Labs' score of 0.72 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Neumora Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioAge Labs has higher revenue and earnings than Neumora Therapeutics. BioAge Labs is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	28.44	-$80.61M	-$2.38	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A

Neumora Therapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -912.26%. BioAge Labs' return on equity of -28.99% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-912.26%	-28.99%	-27.09%
Neumora Therapeutics	N/A	-242.28%	-131.32%

BioAge Labs currently has a consensus price target of $33.00, indicating a potential upside of 492.46%. Neumora Therapeutics has a consensus price target of $6.57, indicating a potential upside of 1,675.10%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Neumora Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

BioAge Labs has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.95, suggesting that its stock price is 195% more volatile than the broader market.

47.7% of Neumora Therapeutics shares are held by institutional investors. 17.6% of BioAge Labs shares are held by insiders. Comparatively, 26.9% of Neumora Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Neumora Therapeutics beats BioAge Labs on 9 of the 14 factors compared between the two stocks.

How does Neumora Therapeutics compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

In the previous week, Neumora Therapeutics had 1 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 3 mentions for Neumora Therapeutics and 2 mentions for Eyepoint Pharmaceuticals. Neumora Therapeutics' average media sentiment score of 1.37 beat Eyepoint Pharmaceuticals' score of 0.46 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neumora Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eyepoint Pharmaceuticals has higher revenue and earnings than Neumora Therapeutics. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	8.44	-$231.96M	-$3.74	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A

Neumora Therapeutics has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Eyepoint Pharmaceuticals' return on equity of -135.81% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Neumora Therapeutics	N/A	-242.28%	-131.32%

Eyepoint Pharmaceuticals presently has a consensus target price of $25.70, suggesting a potential upside of 737.13%. Neumora Therapeutics has a consensus target price of $6.57, suggesting a potential upside of 1,675.10%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Neumora Therapeutics is more favorable than Eyepoint Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Neumora Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Eyepoint Pharmaceuticals has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.95, meaning that its stock price is 195% more volatile than the broader market.

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Neumora Therapeutics beats Eyepoint Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Neumora Therapeutics compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

In the previous week, Vanda Pharmaceuticals had 2 more articles in the media than Neumora Therapeutics. MarketBeat recorded 5 mentions for Vanda Pharmaceuticals and 3 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.37 beat Vanda Pharmaceuticals' score of 0.48 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neumora Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neumora Therapeutics has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -127.41%. Vanda Pharmaceuticals' return on equity of -49.81% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Neumora Therapeutics	N/A	-242.28%	-131.32%

Vanda Pharmaceuticals presently has a consensus target price of $13.08, suggesting a potential upside of 204.26%. Neumora Therapeutics has a consensus target price of $6.57, suggesting a potential upside of 1,675.10%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Neumora Therapeutics is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Neumora Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Vanda Pharmaceuticals has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.95, meaning that its stock price is 195% more volatile than the broader market.

88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 26.9% of Neumora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Vanda Pharmaceuticals has higher revenue and earnings than Neumora Therapeutics. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.20	-$220.47M	-$4.63	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A

Summary

Neumora Therapeutics beats Vanda Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Neumora Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NMRA vs. The Competition

Export

Metric	Neumora Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$82.17M	$12.37B	$7.26B	$13.21B
Dividend Yield	N/A	2.63%	2.52%	22.89%
P/E Ratio	-0.30	652.86	204.95	19.81
Price / Sales	N/A	749.54	562.00	81.34
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	0.60	9.21	10.75	6.03
Net Income	-$236.93M	$2.83B	$3.50B	$380.34M
7 Day Performance	-20.95%	-3.42%	-2.90%	-2.34%
1 Month Performance	-62.96%	-7.48%	-7.37%	-5.31%
1 Year Performance	-79.43%	-5.62%	2.97%	-2.94%

Neumora Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NMRA Neumora Therapeutics	4.2678 of 5 stars	$0.37 -15.3%	$6.57 +1,675.1%	-80.1%	$82.17M	N/A	N/A	63	News Coverage Positive News
RLMD Relmada Therapeutics	2.8003 of 5 stars	$3.48 -3.3%	$12.00 +244.8%	+66.3%	$371.21M	N/A	N/A	17
FENC Adherex Technologies	4.4797 of 5 stars	$10.62 +4.1%	$17.00 +60.1%	+20.6%	$358.41M	$59.22M	N/A	35	Positive News
BIOA BioAge Labs	3.2128 of 5 stars	$6.36 -3.8%	$36.57 +475.0%	+1.3%	$303.38M	$8.99M	N/A	62	News Coverage Analyst Upgrade
EYPT Eyepoint Pharmaceuticals	2.5479 of 5 stars	$3.15 -3.1%	$25.70 +715.9%	-77.0%	$280.19M	$31.37M	N/A	214

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NMRA) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neumora Therapeutics (NMRA) Competitors

NMRA vs. RLMD, FENC, BIOA, EYPT, and VNDA

How does Neumora Therapeutics compare to Relmada Therapeutics?

Summary

How does Neumora Therapeutics compare to Adherex Technologies?

Summary

How does Neumora Therapeutics compare to BioAge Labs?

Summary

How does Neumora Therapeutics compare to Eyepoint Pharmaceuticals?

Summary

How does Neumora Therapeutics compare to Vanda Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA vs. The Competition

Neumora Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neumora Therapeutics (NMRA) Competitors

NMRA vs. RLMD, FENC, BIOA, EYPT, and VNDA

How does Neumora Therapeutics compare to Relmada Therapeutics?

Do institutionals and insiders have more ownership in NMRA or RLMD?

Does the media refer more to NMRA or RLMD?

Is NMRA or RLMD more profitable?

Which has stronger valuation & earnings, NMRA or RLMD?

Which has more volatility and risk, NMRA or RLMD?

Do analysts rate NMRA or RLMD?

Summary

How does Neumora Therapeutics compare to Adherex Technologies?

Do insiders and institutionals believe in NMRA or FENC?

Does the media refer more to NMRA or FENC?

Is NMRA or FENC more profitable?

Which has higher earnings and valuation, NMRA or FENC?

Which has more volatility & risk, NMRA or FENC?

Do analysts recommend NMRA or FENC?

Summary

How does Neumora Therapeutics compare to BioAge Labs?

Does the media prefer BIOA or NMRA?

Which has stronger valuation & earnings, BIOA or NMRA?

Is BIOA or NMRA more profitable?

Do analysts rate BIOA or NMRA?

Which has more risk & volatility, BIOA or NMRA?

Do institutionals & insiders believe in BIOA or NMRA?

Summary

How does Neumora Therapeutics compare to Eyepoint Pharmaceuticals?

Does the media prefer EYPT or NMRA?

Which has preferable valuation & earnings, EYPT or NMRA?

Is EYPT or NMRA more profitable?

Do analysts prefer EYPT or NMRA?

Which has more volatility and risk, EYPT or NMRA?

Do insiders & institutionals have more ownership in EYPT or NMRA?

Summary

How does Neumora Therapeutics compare to Vanda Pharmaceuticals?

Does the media prefer VNDA or NMRA?

Is VNDA or NMRA more profitable?

Do analysts prefer VNDA or NMRA?

Which has more volatility and risk, VNDA or NMRA?

Do insiders & institutionals have more ownership in VNDA or NMRA?

Which has preferable valuation & earnings, VNDA or NMRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMRA vs. The Competition

Neumora Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools